Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials of Chk1 Inhibitor SRA737

VANCOUVER , June 5, 2017 /CNW/ –¬†Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today reports on the initial progress of the two ongoing Phase 1 trials of its Chk1 inhibitor, SRA737. In addition, today Sierra is presenting two posters describing the innovative clinical designs of these trials at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago.